Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

A single damaged protein inside one brain cell may seem insignificant. Yet new research shows how that small mistake can ...

Inovio Pharmaceuticals ( ($INO) ) has provided an announcement. On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration ...

The study reveals that environmental stressors do not merely kill bacteria; they can also prime surviving cells to take up resistance genes more ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

With a new year just days away, we hope the following list of the top 10 patents of 2025 sparks interest in the state of ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

By Henry A. Onwubiko“A nation that cannot control its own seeds cannot decide its destiny.” –Captain Ibrahim Troure Genetic engineering, the manipulation of deoxyribonucleic acid (DNA), the hereditary ...

Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.